Clinical spectrum, etiology, and treatment response in neonatal autonomic seizures: A case series Authors: Robin M. Litten, Amy L. Patterson, Amy L. McGregor, Basanagoud Mudigoudar, Nitish Chourasia Published: 2023 ABSTRACT AbstractBackgroundNeonatal autonomic signs such as apnea, cyanosis, pallor, and desaturation rarely occur as isolated ictal phenomena and require a high degree of clinical suspicion in combination with continuous video electroencephalogram (vEEG) to establish a diagnosis.MethodsWe review the clinical profile, etiology, and treatment response in five neonates who presented with apnea as the primary seizure semiology.ResultsIctal apneic episodes were confirmed on continuous vEEG in all five infants within 24–48 h of symptom onset. Seizure etiologies included structural, infectious, and genetic, including a neonate with ANKRD11‐associated KBG syndrome, in which ictal apnea has not been previously described. Acute seizures resolved in all neonates following treatment with a single or combination of antiseizure medications.ConclusionsAbrupt onset and clustering episodes of apnea and oxygen desaturation in term infants should raise suspicion for epileptic seizures. Genetic testing should be considered as part of the diagnostic evaluation for autonomic seizures of unknown etiology. Early diagnosis and treatment of neonatal autonomic seizures may lead to excellent treatment response in the acute setting. Introduction Neonatal seizures are often clinically subtle and difficult to distinguish from normal infant behaviors. 1 Establishing clinical diagnosis of neonatal seizures can be challenging even to the most attentive bedside observer in the intensive care setting, due to the multitude of paroxysmal movements such as jitteriness, sleep myoclonus, and rapid eye movements that can mimic seizures. 2 Commonly described clinical signs in neonatal seizures include limb or facial movements that can be clonic, tonic, or myoclonic, whereas autonomic changes such as apnea, cyanosis, pallor, and desaturation are unlikely to be an ictal manifestation in isolation. 3 , 4 Whenever autonomic symptoms are present without associated motor activity, high clinical suspicion is required in combination with continuous video electroencephalogram (vEEG) monitoring to establish a diagnosis. 4 , 5 , 6 Ictal apnea described as part of autonomic seizures by the ILAE Task Force on neonatal seizures is defined as a distinct alteration of autonomic nervous system function confirmed using vEEG/amplitude‐integrated EEG. 4 Infrequent reports have described neonatal autonomic seizures (predominantly apnea) due to intraventricular hemorrhage, temporal/occipital lobe structural abnormalities, and more recently in developmental and epileptic encephalopathies due to genetic etiologies such as KCNQ2/KCNQ3 pathogenic mutations. 4 In addition, there is a relative paucity of data regarding treatment response to antiseizure medications (ASMs) in neonates with autonomic seizures owing to the rarity of this seizure type. Herein, we review the clinical characteristics, etiology, and treatment response of ictal apnea in five neonates and describe this as a novel presenting seizure type in a neonate with pathogenic ANKRD11 genetic change. Methods A retrospective chart review was performed on five neonates with apneic seizures diagnosed at Le Bonheur Children's Hospital, Memphis, Tennessee, from January 2020 through 2022. Although a systematic chart review to identify patients with ictal apnea was not undertaken, these patients were identified consecutively from our clinical practice with vEEG‐confirmed ictal apnea. All vEEGs were reevaluated by the epileptologists to confirm the semiology as well as ictal/interictal EEG findings. Data collected included age at onset, sex, gestational age, ASMs (sequence of initiation and dosing), vEEG, and brain magnetic resonance imaging (MRI) findings. Other relevant data including echocardiogram, electrocardiogram, and genetic testing results were recorded when available. The study was approved by the Institutional Review Board. Informed consent was waived for the study. Diagnosis and treatment pathway for neonatal seizures At our center, neurological care including diagnosis and management of seizures in the neonatal intensive care unit is coordinated between the neonatal intensivists and the consulting neurology teams. All neonates at high risk or suspected of having seizures undergo diagnostic vEEG to confirm the diagnosis followed by initiation of treatment, if indicated. Diagnostic neurological evaluation includes brain MRI and tests for infectious causes (blood culture, cerebrospinal fluid [CSF] analysis) or genetic/metabolic disorders (chromosomal microarray [CMA], epilepsy genetic panel or whole‐exome sequencing (WES), CSF neurotransmitters, etc.) as indicated in individual cases. The treating physicians follow our neonatal seizure guideline, which suggests the use of either phenobarbital or levetiracetam as first‐ or second‐line ASM. The order of usage of ASMs is at the discretion of the consulting care teams. The recommended dosing range for loading doses of levetiracetam is 40–60 mg/kg, with subsequent maintenance doses ranging between 40 and 100 mg/kg/day divided two times daily. For phenobarbital, the recommended loading dose is 20 mg/kg followed by an initial maintenance dose of 5 mg/kg/day divided twice daily. An additional loading dose of 20 mg/kg for phenobarbital may be considered depending on the seizure burden. Response to treatment is assessed by clinical evaluation of seizure reports and follow‐up vEEGs. Results Table 1 provides a summary of clinical characteristics, etiology, ictal and interictal vEEG, brain MRI findings, and results of genetic testing in the cohort. All five infants presented at term/near term (corrected gestational age) with abrupt onset clustering episodes of apnea and oxygen desaturation (whenever connected to a pulse oximeter). The events were first noticed between 2 days to 4 weeks of life in the five neonates. Patients 1, 2, 3, and 5 were in the neonatal intensive care unit (since birth) where their events were first reported, whereas patient 4 presented to the emergency department after being discharged from the hospital after birth. No accompanying clinical movements were reported at the initial presentation. Ictal apneic episodes were recorded on continuous vEEG in all five infants within 24–48 h of symptom onset. Ictal onset on EEG was seen in the anterior and mid‐temporal regions in four neonates, while the onset was in the posterior temporal–occipital region in patient 2. Clinical apnea was confirmed on vEEG with attenuation of waveforms from the respiratory belt (e.g., patient 2; Figure 1) and vital sign alarms. Clinical apnea and desaturations correlated with ictal epileptiform spike evolution in the temporal region in all infants except patient 3, whose apnea and desaturations correlated with diffuse voltage attenuation of EEG background. Mild extremity stiffening with apnea and desaturation was noted in patient 2 (in two seizures out of 11 on EEG) and patient 4 (in two seizures out of 12 on EEG), correlating with ictal spread of epileptiform waveforms from temporal to frontocentral regions. MRI brain was unremarkable in four neonates except patient 3, who had Dandy–Walker malformation. Genetic testing with CMA revealed trisomy 18 in patient 2 and a pathogenic variant in the ANKRD11 gene in patient 1 (with syndromic/dysmorphic features consisting of microcephaly, large anterior fontanelle, up‐slanting palpebral fissures, facial asymmetry, bilateral fifth‐finger clinodactyly) on WES. Patient 4 had apneic seizures due to Streptococcus pneumoniae meningitis, confirmed on CSF culture. Neonates were treated with either a single or sequential combination of ASM regimens consisting of levetiracetam, phenobarbital, or lacosamide. The acute seizures resolved within 24–72 h in all five neonates following the initiation of treatment. Table 1Clinical, EEG and Etiological details of the cohort.PatientSexGestational age at birthAge at sz onsetSz characterized on continuous EEGMRI FindingsAnti‐seizure medication(s)Time to sz cessation after pharmacologic interventionClinical history Patient 1 M36 weeks40 weeksWithin 24 h of symptom onsetNormalLevetiracetam (60 mg/kg IV LD, 60 mg/kg IV divided BID)Within 24 hFive events of apnea,cyanosis with oxygen desaturation in 24 h; echocardiogram unremarkable, sepsis evaluation negative Patient 2 F38 weeks42 weeksWithin 24 h of symptom onsetNormalLevetiracetam (50 mg/kg IV LD, 50 mg/kg IV MD)Within 24 hFourteen apneic episodes with cyanosis in 24 h with desaturation. On non‐invasive positive pressure ventilation. Sepsis evaluation negative, known cardiac abnormalities. Patient 3 F36 weeks37 weeksWithin 48 h of symptom onsetDandy Walker‐malformation 1. Levetiracetam (40 mg/kg IV LD, 40 mg/kg IV MD)2. phenobarbital (20 mg/kg IV LD and 5 mg/kg IV MD) Within 72 hSix episodes of apnea, desaturation and cyanosis in 24 h, sepsis work up negative; echocardiogram unremarkable Patient 4 M38 + 4 weeks39 + 1 weeksWithin 48 h of symptom onsetNormal 1. Levetiracetam (40 mg/kg IV LD, 60 mg/kg IV MD) 2. Lacosamide (10 mg/kg IV LD, 5 mg/kg IV MD) within 72 hThree episodes of apneas with cyanosis in 1 h; echocardiogram unremarkbale Patient 5 M39 weeks39 + 2 weeksWithin 48 h of symptom onsetNormalLevetiracetam (50 mg/kg IV LD, 40 mg/kg IV MD)Within 24 hThree apnea events with cyanosis in 2 h; echcardiogram unremarkablePatientIctal EEGInterictal EEGDuration of ictal EEG and clinical description of szOther clinical featuresEtiologyOther testing Patient 1 Independent Left temporal (F7/T7) and Right Temporal (F8/T8) onset with rhythmic sharp spikes (8‐14 Hz) with spread to T7/P7/O1 and T8/P8/O2; Six seizures in 24 h on EEG.Multifocal sharp transients predominantly in the left and right temporal regions.70‐90 s; apnea with desaturation in last third of seizureMicrocephaly, large anterior fontanelle, up‐slanting palpebral fissures, facial asymmetry, bilateral fifth finger clinodactyly, sacral dimple, hypotonia, IUGRWhole exome sequencing: Pathogenic variant in ANKRD11 c.4087 C > T (p.Arg1363Ter) consistent with KBG syndrome.CMA: normal; epilepsy panel: VUS in C12 or f57, DOCK7, RNASEH2B, SCN2A, and SPATA5 Patient 2 Ten independent seizures with rhythmic 1‐2 Hz spikes from right posterior temporal‐occipital region (o2 > P8/P4) with in T8/P8 and O2 maximum and subsequent right posterior quadrant evolution. One electroclinical seizure with 1‐2 Hz spikes from left posterior temporal occipital region (T7/P7 and O1) with evolution involving the left posterior quadrant.Mild excessive discontinuity for age; Multifocal sharp transients temporal, parieto‐occpital regions70‐120 s; apnea noted towards the last third of the seizures. Two out of the 11 seizures had focal motor stiffening of extremities.TOF, VSD, double outlet right ventricle, h/o NEC, IUGRTrisomy 18N/A Patient 3 Three electroclinical seizures recorded with rhythmic left fronto‐temporal (F7/T7) sharp waves at onset followed by generalized attenuation of background and rhythmic sharp waves.Multifocal sharp transeints left frontal‐temporal, left fronto‐central, right fronto‐temporal120‐180 s; apnea with desaturation correlating with background voltage attenuationbilateral congenital cataracts, coloboma, Dandy Walker malformationUnknownCMA normal, Epilepsy panel: VUS in GLDC Patient 4 Independent Left temporal (F7/T7) and Right temporal(F8/T8) rhythmic sharp wavesExcessive multi‐focal sharp transients in left and right temporal regions.70‐100 s, apnea with desturation within 30 s of ictal onset. Two of 12 seizures with focal motor stiffening.None S. pneumoniae meningitisN/A Patient 5 Rhythmic sharp waves from left mid‐to‐posterior temporal region (T7/P7)Excessive multi‐focal sharp transients in left and right temporal regions.70 s,with apnea and desaturation towards the last third of seizureNoneUnknownCSF negative for infection, normal CSF neurotransmitters Legend: M – male, F ‐ female, sz ‐ seizure, LD ‐ loading dose, MD ‐ maintenance dose, IV ‐ intravenous, BID (bis in die) ‐ two times daily, mg ‐ milligram, kg ‐ kilogram, F ‐ frontal, T ‐ temporal, O ‐ occipital, P‐ parietal, Hz ‐ hertz, EEG – electroencephalogram, s ‐ seconds, VUS ‐ variant of uncertain significance, TOF ‐ tetralogy of Fallot, VSD ‐ ventricular septal defect, IUGR ‐ intrauterine growth restriction, NEC ‐ necrotizing enterocolitis, h/o ‐ history of, GLDC ‐ glycine decarboxylase, CSF ‐ cerebrospinal fluid, CMA ‐ chromosomal microarray, ANKRD11 ‐ ankyrin repeat domain 11, DOCK7 ‐ Dedicator Of Cytokinesis 7, RNASEH2B ‐ Ribonuclease H2 subunit B, SCN2A ‐ Sodium channel protein type 2 subunit alpha, SPATA5 ‐ Spermatogenesis Associated 5, C12orf57 – chromosome 12 open reading frame 57, N/A – not applicableJohn Wiley & Sons, Ltd. Clinical, EEG and Etiological details of the cohort. 1. Levetiracetam (40 mg/kg IV LD, 40 mg/kg IV MD)2. phenobarbital (20 mg/kg IV LD and 5 mg/kg IV MD) 1. Levetiracetam (40 mg/kg IV LD, 60 mg/kg IV MD) 2. Lacosamide (10 mg/kg IV LD, 5 mg/kg IV MD) Legend: M – male, F ‐ female, sz ‐ seizure, LD ‐ loading dose, MD ‐ maintenance dose, IV ‐ intravenous, BID (bis in die) ‐ two times daily, mg ‐ milligram, kg ‐ kilogram, F ‐ frontal, T ‐ temporal, O ‐ occipital, P‐ parietal, Hz ‐ hertz, EEG – electroencephalogram, s ‐ seconds, VUS ‐ variant of uncertain significance, TOF ‐ tetralogy of Fallot, VSD ‐ ventricular septal defect, IUGR ‐ intrauterine growth restriction, NEC ‐ necrotizing enterocolitis, h/o ‐ history of, GLDC ‐ glycine decarboxylase, CSF ‐ cerebrospinal fluid, CMA ‐ chromosomal microarray, ANKRD11 ‐ ankyrin repeat domain 11, DOCK7 ‐ Dedicator Of Cytokinesis 7, RNASEH2B ‐ Ribonuclease H2 subunit B, SCN2A ‐ Sodium channel protein type 2 subunit alpha, SPATA5 ‐ Spermatogenesis Associated 5, C12orf57 – chromosome 12 open reading frame 57, N/A – not applicable Patient 2: (Top) Ictal electroencephalogram onset in the right parieto‐occipital region with evolution involving spread to the right temporal region (bottom). Arrow (bottom) shows the onset of apnea with the attenuation of respiratory waveforms (see abdominal belt) in relation to seizure onset (top). Discussion We detail five neonates with abrupt onset and clustering episodes of ictal apnea with oxygen desaturation confirmed by continuous vEEG monitoring. All had resolution of acute seizures following treatment with a single or combination of two ASMs. We describe focal autonomic seizures with apnea as a novel initial seizure manifestation in a neonate with a pathogenic variant in the ANKRD11 gene associated with KBG syndrome. Neonatal autonomic seizures characterized by alteration in cardiovascular, sudomotor, vasomotor, pupillary, and thermoregulatory function as the predominant seizure type have been proposed as a distinct seizure semiology in neonates. 4 These symptoms may also involve respiration (apnea) and are rarely known to occur in isolation. 4 , 6 Previous reports have described neonatal ictal apnea with or without additional motor symptoms. 7 , 8 , 9 , 10 Onset of neonatal apneic seizures in our cohort ranged between 2 days to 4 weeks of life. In published cases, the time to first apneic seizure varied between a few days to weeks in neonates with unknown or genetic etiologies, whereas these were noted to occur shortly after birth in acute symptomatic etiologies (such as hemorrhage, hypoxia, and infection). 6 , 8 , 9 , 11 , 12 , 13 In our cohort, the clinical features of the five infants on vEEG consisted predominantly of apnea and oxygen desaturation. In a minority of seizures in two neonates (patients 2 and 4), some subtle stiffening of extremities was seen, which correlated with the spread of ictal epileptiform waveforms to frontocentral regions. Therefore, a high index of suspicion is essential to diagnose seizures as the cause of abrupt onset, unexplained clustering episodes of apnea in term neonates, especially once other more likely etiologies (such as otolaryngological, cardiac, or respiratory) are ruled out. In Figure 2, we summarize a diagnostic approach to neonates presenting with unexplained autonomic symptomatology. Proposed approach to neurological evaluation in neonates with unexplained autonomic symptomatology. ASM, antiseizure medication; CMA, chromosomal microarray; EEG, electroencephalogram; EGP, epilepsy genetic panel; MRI, magnetic resonance imaging; WES, whole‐exome sequencing. All five patients had ictal abnormalities in the temporal region (frontotemporal, temporo‐occipital) at onset, with ictal evolution in the temporal lobe corresponding with clinical apnea and desaturation in four neonates. This is in agreement with previous reports 11 suggesting that the limbic system is the site of origin for apneic seizures, similar to older infants, children, and adults. 14 , 15 One neonate had an onset of clinical apnea correlating with diffuse voltage attenuation, which has also been previously reported. 16 Recent individual case reports have emphasized apneic seizures in full‐term neonates as the presenting symptom of temporal lobe intracranial hemorrhage, 8 , 11 although this has been described in other etiologies including hypoxia, sepsis, and more recently in some genetic conditions. Self‐limited familial neonatal‐infantile epilepsy (SeLFNIE) and developmental epileptic encephalopathy phenotypes associated with pathogenic variants in KCNQ2/KCNQ3, SCN2A, and SCN8A have been associated with tonic stiffening accompanied by apnea, pallor, and cyanosis as the first presenting symptom. 12 , 17 In our cohort, we describe a neonate with pathogenic ANKRD11 gene mutation (on WES) and dysmorphic features consistent with KBG syndrome noted to have apnea and desaturation, expanding the spectrum of seizure types associated with this genetic condition. Epilepsy phenotypes previously described from infancy to teenage years in this genetic disorder include generalized tonic–clonic, absence, myoclonic, focal, and nonconvulsive seizures characterized by prolonged impaired awareness. 13 , 18 , 19 Trisomy 18 as in patient 2 in our series has been previously described to be associated with apneic seizures. 18 In the absence of acute symptomatic etiologies, genetic testing such as CMA (in syndromic/dysmorphic cases), next‐generation sequencing (epilepsy genetic panels), or WES should be considered in neonates with seizures with or without dysmorphic features (Figure 2). Because this seizure type is rare, there is a paucity of information on recent ASM use and response to treatment in neonatal apneic seizures. A recent systematic review that included 13 neonates with ictal apnea from eight different studies noted that phenobarbital was the most commonly used first‐line ASM in 10 patients and led to seizure resolution in eight, while two patients required an additional ASM. 6 Levetiracetam was used in two neonates, and both showed good response. 6 In our cohort, levetiracetam was used successfully as the first ASM in all neonates with seizure resolution in three of the five neonates, while patients 3 and 4 achieved seizure resolution after the addition of phenobarbital and lacosamide, respectively. In agreement with prior findings, this seizure type has been associated with excellent response to ASMs. 6 Our observations, however, may not be generalizable to all neonates with autonomic seizures since the majority in our series had normal MRI, and our cohort did not include etiologies with a higher seizure burden such as intracranial hemorrhage/infarct or hypoxic–ischemic encephalopathy. Nonetheless, our findings highlight the clinical spectrum of presentation and treatment response to ASMs in neonatal apneic seizures relevant to current clinical practice. A small single‐center cohort and retrospective methodology are major limitations of our study, although rarity of isolated apnea as a seizure manifestation in neonates limits the availability of data even in large cohorts. 20 Neonatal apnea generally tends to occur secondary to underlying causes such as birth asphyxia, infections, metabolic derangements, and congenital anomalies, but due to the inherent limitations of a retrospective case series design, we cannot accurately define the frequency of apnea caused by these etiologies compared with ictal apnea in our cohort. Choice and dosing of ASMs also varied among the neonates treated in our cohort, limiting the generalizability of treatment responses. Based on current evidence, levetiracetam is not a preferred first‐line medication for neonatal seizures. 21 , 22 Conclusion Abrupt onset and clustering episodes of apnea and oxygen desaturation in term infants should raise suspicion for epileptic seizures. Genetic testing should be considered as part of the etiological evaluation of autonomic seizures of unknown causes. Early diagnosis and treatment of neonatal autonomic seizures may lead to excellent treatment response in the acute setting. Author Contributions Robin M. Litten: Data curation; writing—original draft. Amy L. Patterson: Writing—review and editing. Amy L. McGregor: Writing—review and editing. Basanagoud Mudigoudar: Writing—review and editing. Nitish Chourasia: Conceptualization; data curation; methodology; writing—original draft; writing—review and editing. Conflicts of Interest The authors declare no conflicts of interest.